New alliance will target major risk factor for Alzheimer's

A new collaboration will see four leading academic research laboratories working with AstraZeneca to study a major risk factor for Alzheimer's disease. Steven Paul, M.D., of Weill Cornell Medical College and AstraZeneca jointly announced the A5 Alliance. Collectively, the alliance will examine the apolipoprotein E4 genotype (ApoE). “We are convinced that ApoE represents a major piece of the Alzheimer's disease puzzle,” Paul noted. Additional members include David Holtzman, M.D. of Washington University in St. Louis, Peter Davies, Ph.D., of The Feinstein Institute for Medical Research and Cheryl Wellington, Ph.D., of the University of British Columbia.